Fourth Generation HIV Testing and New Diagnostic Algorithms for Detecting HIV Infection
|
|
- Gerald Blair
- 7 years ago
- Views:
Transcription
1 A Publication of Warde Medical Laboratory 2012 Volume 22, Number 4 Quality in Laboratory Diagnosis Fourth Generation HIV Testing and New Diagnostic Algorithms for Detecting HIV Infection William G. Finn, M.D. I n April of this year, Warde Medical Laboratory switched to a fourth-generation screening platform for detection of infection by human immunodeficiency virus (HIV). The fourth generation platform available for some time in Europe but only recently FDA New testing detects approved in the US HIV-1 p24 antigen differs from third and HIV-1, HIV-2, generation platforms and HIV-O variant in the addition of detection of the antibodies. HIV-1 p24 antigen in the initial ELISA screen1. Fourth generation screening platforms also continue to detect antibodies directed against HIV-1, HIV-2, and HIV-O variant as was the case with the previous generation of HIV screening methods. In addition to updating the initial screen for HIV, Warde has also changed the positivescreen follow-up with testing that follows a diagnostic algorithm proposed by the U.S. Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL), and formally adopted by the Clinical Laboratory Standards Institute (CLSI) (Figure 1)2. According to this algorithm, the previous step of Western Blot confirmation is replaced by a rapid test for discrimination of HIV-1 from HIV-2 infection ( Multi-Spot, BioRad), and, if necessary in the case of discordant results, nucleic acid testing (NAT) for HIV-1. Currently, two manufacturers (Abbott and BioRad) make FDA-approved fourth generation screening platforms. Also In This Issue: 7 Editorial Limitations of Virus Culture
2 Fourth Generation HIV Testing and New Diagnostic Algorithms for Detecting HIV Infection 2 Figure 1. A new algorithm for HIV screening, as proposed by CDC/ APHL, and adopted by CLSI (Figure adapted from Styer et al, 2011) HIV-1/HIV-2 EIA 4 th generation screen Non-Reactive Repeatedly Reactive Report as Non-Reactive HIV-1/HIV-2 Discriminatory Assay (MultiSpot) HIV-1 Reactive, HIV-2 Non-Reactive HIV-1 Non-Reactive, HIV-2 Reactive HIV-1 Non-Reactive, HIV-2 Non-Reactive Report as HIV-1 Positive Report as HIV-2 Positive HIV-1 RNA Nucleic Acid Testing (NAT) Not Done Not Detected Detected Report as HIV Indeterminate Report as HIV-1 Negative Report as HIV-1 Positive
3 3 High rates of HIV transmission happen before HIV-antibodies develop to a detectable level. Warde is using the BioRad Evolis platform for this purpose. The rapid HIV-1/HIV-2 test as adopted by the CDC/APHL/CLSI algorithm is currently manufactured only by BioRad as the MultiSpot assay. There are several advantages to the new diagnostic algorithm. First, the inclusion of p24 antigen detection in the initial screen allows for the earlier detection of new HIV infection by days or weeks compared to third-generation platforms. Studies have shown that the highest rate of HIV transmission occurs during a period of p24 antigenemia (generally detectable 2 to 3 weeks after initial infection) that precedes the development of detectable anti-hiv antibodies (which may take 3 to 12 weeks to develop to detectable levels) 3. It is hoped that the ability to detect HIV infection during this early window period may help to slow the rate of HIV transmission among the population. Second, the new algorithm allows for the rapid distinction between antibodies directed against HIV-1 from antibodies directed against HIV-2. Currently, HIV-2 infection (still quite rare in North America) may cross-react with the HIV-1 Western blot, causing false-indeterminate or falsepositive results (see below) 4. Third, the MultiSpot assay will likely decrease the cost and turnaround time associated with determination of HIV status in infected individuals. While Western blot has high specificity and positive predictive value for HIV-1 infection, it is relatively insensitive compared to newer methods, and there is the potential for cross-reactivity with HIV-2 4. Western blot may also have a relatively high rate of false-indeterminate results, especially in low-prevalence populations. Indeterminate results on HIV-1 Western blot (i.e. one or more bands present, but not fulfilling CDC criteria for a positive result) may indicate either a crossreacting antibody in an HIV-negative patient, cross-reacting antibodies in an HIV-2 positive patient, or early HIV-1 infection. Therefore, indeterminate Western blot results currently are issued with a recommendation to re-test in 4 weeks to assess for the acquisition of additional bands that may indicate early HIV infection. While this has the potential to detect early HIV infection, it can also cause undue anxiety in HIV-negative patients who may harbor cross-reacting antibodies to HIV. Indeed, in a study performed by CDC of blood donors who screened positive for HIV and had indeterminate Western blot results due to antibodies against HIV GAG proteins, only 5 of 209 eventually seroconverted over a 2-year period, and those who did seroconvert did so on their first repeat sample 5. At the time, the CDC indicated that individuals with persistent indeterminate Western blot results without acquisition of new bands should be considered HIV negative. In the new algorithm, a repeatedly positive fourthgeneration screen will be tested via MultiSpot. If MultiSpot reveals antibodies to HIV-1, then the tested sample is considered positive for HIV-1. If the MultiSpot reveals antibodies to HIV-2, then the tested sample is considered positive for HIV-2. If the MultiSpot is negative in the setting of a positive fourth generation screen, then the algorithm
4 Fourth Generation HIV Testing and New Diagnostic Algorithms for Detecting HIV Infection 4 HIV-2 infection remains quite rare in individuals native to North America. proceeds to HIV nucleic acid testing (NAT). If NAT is positive for HIV-1, then the patient is considered positive for HIV-1. If NAT is negative for HIV-1, then the patient is considered negative for HIV-1 6,7. Referring clinicians will have to make individual determinations regarding any potential need for HIV-2 nucleic acid testing in patients with positive initial 4 th generation screens but non-reactive MultiSpot assays and negative HIV-1 NAT results. At present there is not an FDAapproved NAT assay for detection of primary HIV-2 infection, but non-fda-approved HIV-2 NAT is available as a sendout through Warde. Clients should keep in mind, however, that HIV-2 infection remains quite rare in individuals native to North America. 90% of reported HIV-2 cases in the US are from individuals who have immigrated from African nations, mainly in west Africa. Fewer than 170 cases of HIV-2 infection were confirmed by CDC between 1987 and 2009 (constituting only 0.01% of the more than 1.4 million cases of HIV infection during that time period), and only 3% of these cases (5 individuals) were born in the United States 8. Since NAT requires a sample that has not been previously tested (due to the sensitivity of NAT and concerns for contamination), and since NAT should be done within 72 hours of sample acquisition, Warde will report samples with positive 4 th generation screens and negative MultiSpot assays as HIV INDETERMINATE, with a recommendation to pursue HIV-1 NAT on a repeat sample. Results for specimens sent to Warde/MCL for primary screening for HIV will be reported in one of four ways, as outlined in Figures 2 through 5. Since CDC/APHL/CLSI guidelines still allow for alternative diagnostic algorithms that include Western blot confirmation, Warde will continue to offer Western blot testing to those clients that wish to pursue this test after a positive HIV screen in their own laboratory. However, when a sample is sent to Warde for primary screening, positive screens will be tested via MultiSpot, rather than by Western blot. Figure 2 For patient samples non-reactive on initial 4 th generation EIA screen, the following result will be issued: HIV NON-REACTIVE
5 5 Figure 3 For patient samples that are repeatedly reactive on the fourth-generation EIA screen and also reactive for HIV-1 on the MultiSpot Assay, the following result will be issued: HIV-1 POSITIVE This sample was repeatedly reactive by a 4 th generation HIV screening method, and also reactive for HIV-1 by the MultiSpot differentiation assay. According to an algorithm proposed by the CDC and adopted by the Clinical Laboratory Standards Institute (CLSI), a sample with this profile should be considered positive for HIV-1. If this is the first positive sample from this patient, we recommend repeat screening on a separately drawn sample. If further confirmation of a positive result is deemed necessary on clinical grounds, then HIV nucleic acid testing may be appropriate (refer to test code TMAHIV). Figure 4 For patient samples that are repeatedly reactive on the fourth-generation EIA screen and also reactive for HIV-2 on the MultiSpot Assay, the following result will be issued: HIV-2 POSITIVE This sample was repeatedly reactive by a 4 th generation HIV screening method, and also reactive for HIV-2 by the MultiSpot differentiation assay. According to an algorithm proposed by the CDC and adopted by the Clinical Laboratory Standards Institute (CLSI), a sample with this profile should be considered positive for HIV-2. If this is the first positive sample from this patient, we recommend repeat screening on a separately drawn sample. If further confirmation of a positive result is deemed necessary on clinical grounds, then HIV-2 nucleic acid testing may be appropriate.
6 Fourth Generation HIV Testing and New Diagnostic Algorithms for Detecting HIV Infection 6 Figure 5 For patient samples that are repeatedly reactive on the fourth-generation EIA screen but non-reactive for both HIV-1 and HIV-2 on the MultiSpot Assay, the following result will be issued: HIV INDETERMINATE HIV NUCLEIC ACID TESTING ON A REPEAT SAMPLE IS RECOMMENDED (TEST CODE TMAHIV) This sample was repeatedly reactive by a 4 th generation HIV screening method, but was non-reactive for both HIV-1 and HIV-2 by the MultiSpot differentiation assay. According to an algorithm proposed by the CDC and adopted by the Clinical Laboratory Standards Institute (CLSI), a sample with this profile should be evaluated by HIV nucleic acid testing. Nucleic acid testing cannot be performed on the same specimen used for the initial screen. Please resubmit a new specimen for HIV-1 nucleic acid testing (refer to test code TMAHIV for proper sample requirement). References 1. Titus, Karen. In new HIV guideline, 20+ years of change. CAP Today 26, no. 3 (2012): Clinical Laboratory Standards Institute. Criteria for laboratory testing and diagnosis of human immunodeficiency virus infection; approved guidelines (CLSI document M53-A). Vols. 31, no. 13. Wayne, PA: Clinical Laboratory Standards Institute, Das, G, P Baglioni, and O Onyebuchi. Primary HIV infection. BMJ 341 (2010): c Torian, Lucia V, Lisa A Forgione, Amado E Punsalang, Robert E Pirollo, and William R Oleszko. Comparison of Multispot EIA with Western blot for confirmatory serodiagnosis of HIV. Journal of Clinical Virology 52S (2011): s41-s Centers for Disease Control (CDC). Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR 38(suppl 7) (1989): Masciotra, Silvina, J Steven McDougal, J Feldman, Patrick Sprinkle, Laura Wesolowski, and S Michele Owen. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. Journal of Clinical Virology 52S (2011): S17-S Styer, Linda M, and Timothy J, Parker, Monica M Sullivan. Evaluation of an alternative supplemental testing strategy for HIV diagnosis by. Journal of Clinical Virology 52S (2011): S35-S Centers for Disease Control and Prevention (CDC). HIV-2 infection surveillance United States MMWR 60, no. 29 (2011):
7 7 Limitations of Virus Culture Danny L. Wiedbrauk, Ph.D., Scientific Director, Virology and Molecular Biology PCR testing is the new gold standard for several viral agents. For decades, virus cultures have been the gold standard for virus detection despite their long turnaround times and lack of sensitivity. Polymerase Chain Reaction (PCR) tests have become the new gold standard for several viral agents because PCR tests are (a) more sensitive, (b) detect even the unculturable viral strains, and (c) provide results within a clinically relevant timeframe. For these reasons, we do not recommend virus culture for detecting cytomegalovirus (CMV), enteroviruses, noroviruses, rhinoviruses, respiratory syncytial virus (RSV) and varicella-zoster virus (VZV). Cytomegalovirus CMV grows slowly in cell culture and positive results are not available for 8-21 days after inoculation. Dual infections are relatively common in deep respiratory specimens and faster growing viruses will often destroy the culture before CMV can be detected resulting in false negative culture results. PCR results are available in 1-2 days and detection is not affected by the presence of other viruses. Enteroviruses There are more than 60 different enteroviruses and multiple serotypes circulate concurrently. Many enteroviruses are difficult or impossible to grow in culture. Positive enterovirus cultures are usually reported 3-8 days after inoculation; negative results are not available for days. PCR results are available in 1-2 days and PCR methods can detect all enterovirus types. Noroviruses Noroviruses are the most common cause of sporadic gastroenteritis and gastroenteritis outbreaks in the United States 1. Noroviruses cannot be grown in culture. PCR methods take 1-2 days. Antigen detection is very insensitive. Rhinoviruses There are more than 200 different rhinoviruses and multiple serotypes circulate simultaneously. Virus isolation has been the primary means for detecting rhinovirus infections but culture is very insensitive and culture does not detect all strains. PCR is the preferred method for detecting rhinovirus infections 2.
8 8 Limitations of Virus Culture Respiratory Syncytial Virus RSV is the major cause of bronchiolitis and pneumonia in children under 5 years of age 3. Virus cytopathology is usually detectable 5-8 days after inoculation and the sensitivity of virus culture ranges from 57-90% depending upon the virus subtype 3. PCR testing is reported to be 2.6 fold more sensitive than culture 3 and test results are available in 1-2 days. Varicella-Zoster Virus Varicella-zoster virus causes chickenpox and shingles. VZV grows slowly in culture and viral cytopathology is usually detected 7-10 days after inoculation. Rapid shell vial cultures can detect VZV in 3-5 days. PCR is more sensitive than culture 4 and results are available 1-2 days after specimen submission. Literature Cited 1. American Academy of Pediatrics. Human Calicivirus Infections (Norovirus and Sapovirus). In: Pickering, LK, Baker CJ, Kimberlin DW, Long SS. Red Book: 2012 report of the Committee on Infectious Diseases. Elk Grove Villiage, IL. American Academy of Pediatrics, 2012: American Academy of Pediatrics. Rhinovirus Infections. In: Pickering, LK, Baker CJ, Kimberlin DW, Long SS. Red Book: 2012 report of the Committee on Infectious Diseases. Elk Grove Villiage, IL. American Academy of Pediatrics, 2012: Robinson CC. Respiratory Viruses. In: Specter S, Hodinka RL, Young SA, Wiedbrauk DL. Clinical Virology Manual, Fourth Edition. ASM Press, Washington DC. 2009; Stránská R, Schuurman R, de Vos M, van Loon AM. Routine use of a highly automated and internally controlled real-time PCR assay for the diagnosis of herpes simplex and varicella-zoster virus infections. J. Clin Virol. 2004;30(1): William G. Finn, M.D., Medical Director Richard S. Bak, Ph.D., Operations Director Direct Correspondence to: Editor: The Warde Report Warde Medical Laboratory 300 Textile Road Ann Arbor, MI / Toll free Fax
Suggested Reporting Language for the HIV Laboratory Diagnostic Testing Algorithm
Suggested Reporting Language for the HIV Laboratory Diagnostic Testing Algorithm November 2013 Introduction In March 2010, the Centers for Disease Control and Prevention (CDC) and the Association of Public
More informationINTERPRETATION INFORMATION SHEET
Creative Testing Solutions 2424 West Erie Dr. 2205 Highway 121 10100 Martin Luther King Jr. St. No. Tempe, AZ 85282 Bedford, TX 76021 St. Petersburg, FL 33716 INTERPRETATION INFORMATION SHEET Human Immunodeficiency
More informationin hiv diagnostics the role of phls
Issues in Brief: HIV Diagnostics UPDATE Association of Public Health Laboratories August 2011 Conference calls Focus on New trends in hiv diagnostics the role of phls In February 2011, the Association
More informationTesting Oral Presence of
Issues in Brief: Oral Fluid Testing for HIV Antibodies February 2013 Testing Oral Fluid for the Presence of HIV Antibodies 2013 Status Report HIV testing is primarily done using blood-based specimens (fingerstick
More informationDiagnosis of HIV-1 Infection. Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University
Diagnosis of HIV-1 Infection Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University Tests Used to Diagnose HIV-1 Infection HIV antibody (today s topic) HIV p24 antigen HIV DNA HIV
More informationAlgorithm for detecting Zika virus (ZIKV) 1
Algorithm for detecting Zika virus (ZIKV) 1 This algorithm is addressed to laboratories with established capacity (molecular, antigenic and/or serological) to detect dengue (DENV), Zika (ZIKV) 2, and chikungunya
More informationQuality Assurance Guidelines for Testing Using Rapid HIV Antibody Tests Waived Under the Clinical Laboratory Improvement Amendments of 1988
Quality Assurance Guidelines for Testing Using Rapid HIV Antibody Tests Waived Under the Clinical Laboratory Improvement Amendments of 1988 U.S. Department of Health and Human Services Centers for Disease
More information4A. Types of Laboratory Tests Available and Specimens Required. Three main types of laboratory tests are used for diagnosing CHIK: virus
4. LABORATORY 4A. Types of Laboratory Tests Available and Specimens Required Three main types of laboratory tests are used for diagnosing CHIK: virus isolation, reverse transcriptase-polymerase chain reaction
More informationU.S. Public Health Service Guidelines for Testing and Counseling Blood and Plasma Donors for Human Immunodeficiency Virus Type 1 Antigen
March 1, 1996 / Vol. 45 / No. RR-2 Recommendations and Reports U.S. Public Health Service Guidelines for Testing and Counseling Blood and Plasma Donors for Human Immunodeficiency Virus Type 1 Antigen U.S.
More informationZika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases
Zika Virus Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases What is the incubation period for Zika virus infection? Unknown but likely to be several
More informationAcute infections, cost per infection and turnaround time in three U.S. hospital laboratories
1 Acute infections, cost per infection and turnaround time in three U.S. hospital laboratories using fourth-generation antigen-antibody HIV immunoassays Laura G. Wesolowski 1,*, Muazzam Nasrullah 1, Robert
More informationViral Hepatitis. 2009 APHL survey report
Issues in Brief: viral hepatitis testing Association of Public Health Laboratories May Viral Hepatitis Testing 9 APHL survey report In order to characterize the role that the nation s public health laboratories
More informationGuidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011
Guidelines for TB Blood Testing Minnesota Department of Health TB Prevention and Control Program June 2011 Outline Interferon-Gamma Release Assays aka TB blood tests 1. What are they? 2. What are the current
More information41 Viral rashes and skin infections
41 Viral rashes and skin infections Clinical There are several kinds of skin infections caused by viruses, and these are best considered in the four categories that group together similar symptoms for
More informationReducing the Diagnostic Window for Acute HIV
Reducing the Diagnostic Window for Acute HIV ARCHITECT HIV Ag/Ab Combo See intended use and important safety information on the next page. The Clinical and Economic Value of Early Detection Using 4 th
More informationHow Does a Doctor Test for AIDS?
Edvo-Kit #S-70 How Does a Doctor Test for AIDS? S-70 Experiment Objective: The Human Immunodefi ciency Virus (HIV) is an infectious agent that causes Acquired Immunodefi ciency Syndrome (AIDS) in humans.
More informationEVALUATING THE PATIENT WITH AN ACUTE, GENERALIZED VESICULAR OR PUSTULAR RASH ILLNESS AND DETERMINING THE RISK OF SMALLPOX
EVALUATING THE PATIENT WITH AN ACUTE, GENERALIZED VESICULAR OR PUSTULAR RASH ILLNESS AND DETERMINING THE RISK OF SMALLPOX Many rash illnesses can present with vesicles and pustules. The purpose of this
More informationHIV DIAGNOSIS: A GUIDE FOR SELECTING RAPID DIAGNOSTIC TEST (RDT) KITS
HIV DIAGNOSIS: A GUIDE FOR SELECTING RAPID DIAGNOSTIC TEST (RDT) KITS 1) Overview There are nearly 33 million people infected with the human immunodeficiency virus (HIV) world wide. Sub-Saharan Africa
More informationHepatitis and Retrovirus. LIAISON XL Accurate detection of HIV infection. HIV Ab/Ag FOR OUTSIDE THE US AND CANADA ONLY
Hepatitis and Retrovirus LIAISON XL Accurate detection of HIV infection HIV Ab/Ag FOR OUTSIDE THE US AND CANADA ONLY LIAISON XL HIV Ab/Ag is Your solution LIAISON XL murex HIV Ab/Ag main features The LIAISON
More informationAIR FORCE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS
AIR FORCE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS An Air Force addendum to the TRI-SERVICE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS Prepared by: Air Force Institute for Operational Health
More informationLyme (IgG and IgM) Antibody Confirmation
Pathology & Laboratory Medicine Lyme (IgG and IgM) Antibody Confirmation TEST UPDATE: New Test Notification Date: 1/9/2013 Effective Date: 1/7/2013 CONTACT INFO Call 802-847-5121 800-991-2799 email labmarketing@vtmednet.org
More informationIllinois Influenza Surveillance Report
ILLINOIS DEPARTMENT OF PUBLIC HEALTH Illinois Influenza Surveillance Report Week 8: Week Ending Saturday, February 25, 2012 Division of Infectious Diseases Immunizations Section 3/5/2012 1 Please note
More informationBackground Information
Background Information r One About NAT Testing NAT testing has been widely embraced by laboratories throughout the world as a means to identify CT cases because of its high degree of accuracy and reliability
More informationCME Article Hiv Disease Surveillance
CME Article Hiv Disease Surveillance hiv disease surveillance cme Collaboration between Medicine and Public Health Sindy M. Paul, md, mph; Helene Cross, phd; Linda Dimasi, mpa; Abdel R. Ibrahim, phd; and
More informationWhat is HIV? What is AIDS? The HIV pandemic HIV transmission Window period Stages of HIV infection
Module 1 Overview of HIV Infection Purpose Pre-requisite Modules Learning Objectives To provide you with the basic terms and concepts related to HIV infection. None At the end of this module, you will
More informationCoding and Billing for HIV Services in Healthcare Facilities
P a g e 1 Coding and Billing for HIV Services in Healthcare Facilities The Hawai i State Department of Health STD/AIDS Prevention Branch is pleased to provide you information on billing and reimbursement
More informationLikely Female-to-Female Sexual Transmission of HIV Texas, 2012
Morbidity and Mortality Weekly Report (MMWR) Likely Female-to-Female Sexual Transmission of HIV Texas, 2012 Weekly March 14, 2014 / 63(10);209 212 Shirley K. Chan, MPH1, Lupita R. Thornton1, Karen J. Chronister,
More informationCoding guide for routine HIV testing in health care settings
Coding guide f routine HIV testing in health care settings Background In September of 2006, CDC issued recommendations f Human immunodeficiency virus (HIV) testing in health care settings. The Revised
More informationChickenpox (Varicella)
Chickenpox (Varicella) DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report within 24 hours confirmed or suspected cases of varicella
More informationHIV TESTING AND D IAGNOSIS IN I NFANTS AND C HILDREN
CHAPTER 1 HIV TESTING AND D IAGNOSIS IN I NFANTS AND C HILDREN 12/04 I. INTRODUCTION Although there have been tremendous advances in the care of HIV-infected adults and children in the last several years,
More informationThe CVN Development Programme a 4-month update
The CVN Development Programme a 4-month update Peter Simmonds Centre for Infectious Diseases University of Edinburgh Edinburgh CVN Development Programme Initiative announced in 2009 to focus development
More informationInfluenza Surveillance Weekly Report CDC MMWR Week 16: Apr 17 to 23, 2016
Office of Surveillance & Public Health Preparedness Program of Public Health Informatics Influenza Surveillance Weekly Report CDC MMWR Week 16: Apr 17 to 23, 2016 Influenza Activity by County, State, and
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Hepatitis B Revised Hepatitis B 1.0 Provincial Reporting Confirmed, chronic and probable cases of disease
More informationDiagnosing arbovirus infections (and Bill s holiday snaps) David W Smith Division of Microbiology and Infectious Diseases PathCentre
Diagnosing arbovirus infections (and Bill s holiday snaps) David W Smith Division of Microbiology and Infectious Diseases PathCentre Arboviral illnesses relevant to Australia Polyarthralgia Fever and rash
More informationCase Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
More informationPreface. TTY: (888) 232-6348 or cdcinfo@cdc.gov. Hepatitis C Counseling and Testing, contact: 800-CDC-INFO (800-232-4636)
Preface The purpose of this CDC Hepatitis C Counseling and Testing manual is to provide guidance for hepatitis C counseling and testing of individuals born during 1945 1965. The guide was used in draft
More informationSOGC recommendation on ZIKA virus exposure for clinicians caring for pregnant women and those who intend to get pregnant
SOGC recommendation on ZIKA virus exposure for clinicians caring for pregnant women and those who intend to get pregnant Foreword The rapid emergence of Zika virus as a potential causative agent for fetal
More informationPoint of care analyzer for definitive cystic fibrosis diagnostics
Technology Offer Summary Point of care analyzer for definitive cystic fibrosis diagnostics A Barcelona based company offers a CE (Conformité Européenne) marked diagnostic test system for the measurement
More informationLIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection
Hepatitis and Retrovirus LIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection FOR OUTSIDE THE US AND CANADA ONLY LIAISON XL HCV Ab is Your solution LIAISON XL murex HCV Ab main features
More informationReconsideration Code 86386. Reconsideration Code Description Nuclear Matrix Protein 22 (NMP22), qualitative
Calendar Year 2013 Centers for Medicare and Medicaid Services (CMS) New and Reconsidered Clinical Laboratory Fee Schedule (CLFS) Test Codes And Final Payment Determinations Reconsideration Code 86386 Reconsideration
More informationBLOOD DONOR TESTING & LOOKBACK STUDIES Shan Yuan, MD Last Updated 2/8/2011. 1. ABO Typing: Performed each time with each donation
Testing Performed: BLOOD DONOR TESTING & LOOKBACK STUDIES Shan Yuan, MD Last Updated 2/8/2011 1. ABO Typing: Performed each time with each donation 2. Rh Typing: o Performed along with ABO typing to determine
More informationNext Generation Sequencing in Public Health Laboratories. 2014 Survey Results
Next Generation Sequencing in Public Health Laboratories 2014 Survey Results MAY 2015 This project was 100% funded with federal funds from a federal program of $215,972. This publication was supported
More informationGLOBAL FUND QUALITY ASSURANCE POLICY FOR DIAGNOSTICS PRODUCTS. (Issued on 14 December 2010, amended on 5 February 2014)
GLOBAL FUND QUALITY ASSURANCE POLICY FOR DIAGNOSTICS PRODUCTS (Issued on 14 December 2010, amended on 5 February 2014) BASIC PRINCIPLES 1. Grant funds provided by the Global Fund may only be used to procure
More information(EMEA/CHMP/BWP/298390/2005)
9 February 2006 Reference: EMEA 06004 PPTA s comments on the proposed Guidelines on Validation of immunoassays for the detection of Hepatitis B Virus surface antigen (HBsAg) (EMEA/CHMP/BWP/298390/2005)
More informationLAB 14 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
STUDENT GUIDE LAB 14 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) GOAL The goal of this laboratory lesson is to explain the concepts and technique of enzyme linked immunosorbent assay (ELISA). OBJECTIVES
More informationSanta Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014. Frequently Asked Questions
Frequently Asked Questions A child has history of BCG vaccination, should they have TST or IGRA? According to the American Academy of Pediatrics Red Book (2012), Interferon Gamma Release Assay (IGRA) is
More informationWhat is an IGRA? What is an IGRA? Are they available here? How do I use them? Learning Objectives
What is an IGRA? Are they available here? How do I use them? Debbie Staley, RN, MPH TB Nurse Consultant VDH Division of Disease Prevention TB Control Program Learning Objectives Participants will be able
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
A. 510(k) Number: K092353 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY B. Purpose for Submission: This is a new 510k application for a new indication for the MONOLISA Anti-HAV IgM EIA
More informationEarly detection of HIV infection in infants and children
Early detection of HIV infection in infants and children Guidance note on the selection of technology for the early diagnosis of HIV in infants and children Summary of recommendations Because of the high
More informationEnhancing Respiratory Infection Surveillance on the Arizona-Sonora Border BIDS Program Sentinel Surveillance Data
Enhancing Respiratory Infection Surveillance on the Arizona-Sonora Border BIDS Program Sentinel Surveillance Data Catherine Golenko, MPH, Arizona Department of Health Services *Arizona border population:
More informationBloodborne Pathogens (HIV, HBV, and HCV) Exposure Management
Bloodborne Pathogens Exposure Policy and Procedures Employees of the State of South Dakota Department of Health Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management PEP Hotline 1-888-448-4911 DOH
More informationHBV DNA < monitoring interferon Rx
Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute
More informationHospitalizations for Hepatitis A, B, and C, Active Component, U.S. Armed Forces, 1991-2011
Hospitalizations for Hepatitis A, B, and C, Active Component, U.S. Armed Forces, 1991-2011 lthough genetically quite distinct from one another, hepatitis viruses A, B, and C all cause inflammatory liver
More informationSyphilis Fast latex Agglutination Test: A Rapid Confirmatory Test for Syphilis
Syphilis Fast latex Agglutination Test: A Rapid Confirmatory Test for Syphilis Martha B. Fears and Victoria Pope* Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases,
More informationTuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
More informationOverview of CLIA-Waived Rapid HIV Tests and the HIV Rapid
Overview of CLIA-Waived Rapid HIV Tests and the HIV Rapid Testing Algorithm (RTA) Project Jacqueline Rurangirwa, MPH Office of AIDS Programs and Policy Planning and Research Division HIV Prevention Planning
More informationLIAISON XL HBsAg Quant
Hepatitis and Retrovirus LIAISON XL HBsAg Quant Reliable detection of HBsAg mutants and genotypes for accurate differential diagnosis of the stage of infection FOR OUTSIDE THE US AND CANADA ONLY LIAISON
More informationLaboratory Testing for Middle East Respiratory Syndrome Coronavirus
Laboratory Testing for Middle East Respiratory Syndrome Coronavirus Interim recommendations (revised) September 2014 1. Introduction The purpose of this document is to provide interim recommendations to
More informationPreamble: Explaining the Technical Aspects of HIV Testing
Preamble: Explaining the Technical Aspects of HIV Testing A. What is the difference between an antibody, antigen, viral load and CD-4 count? The presence of an HIV infection in a person can be determined
More informationTEST METHOD VERIFICATION AND VALIDATION
1 TEST METHOD VERIFICATION AND VALIDATION SWACM 2014 MICHAEL LOEFFELHOLZ, PH.D., ABMM DEPT. PATHOLOGY UNIV TEXAS MEDICAL BRANCH GALVESTON, TX 2 OBJECTIVES Define validation and verification Describe components
More informationDefining Normal Cerebrospinal Fluid White Blood Cell Counts in Neonates and Young Infants: A Scholarly Pursuit
Defining Normal Cerebrospinal Fluid White Blood Cell Counts in Neonates and Young Infants: A Scholarly Pursuit Lori A. Kestenbaum, Jessica L. Ebberson, Joseph J. Zorc, Caitlin LaRussa, Richard L. Hodinka
More informationHEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
More informationMassachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention
Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention Screening Infants and Children for Tuberculosis in Massachusetts Executive Summary In Massachusetts,
More informationFEDERAL PUBLIC SERVICE, HEALTH, FOOD CHAIN SECURITY AND ENVIRONMENT CLINICAL BIOLOGY COMMISSION CLINICAL BIOLOGY SECTION
IPH J. Wytsmanstreet 14 B-1050 Brussels FEDERAL PUBLIC SERVICE, HEALTH, FOOD CHAIN SECURITY AND ENVIRONMENT CLINICAL BIOLOGY COMMISSION CLINICAL BIOLOGY SECTION External Quality Assessment for Molecular
More informationEPIDEMIOLOGY OF HEPATITIS B IN IRELAND
EPIDEMIOLOGY OF HEPATITIS B IN IRELAND Table of Contents Acknowledgements 3 Summary 4 Introduction 5 Case Definitions 6 Materials and Methods 7 Results 8 Discussion 11 References 12 Epidemiology of Hepatitis
More informationEffective Treatment of Lyme Borreliosis with Pentacyclic Alkaloid Uncaria tomentosa (TOA-free Cat s Claw)
Effective Treatment of Lyme Borreliosis with Pentacyclic Alkaloid Uncaria tomentosa (TOA-free Cat s Claw) Executive Summary Introduction In a six-month prospective cohort study designed to compare the
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Verotoxin-producing E. coli infection indicator conditions, including Hemolytic Uremic Syndrome (HUS)
More informationGenetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association
6 Genetic testing The difference diagnostics can make The British In Vitro Diagnostics Association Genetic INTRODUCTION testing The Department of Health published Our Inheritance, Our Future - Realising
More informationHepatitis C 1) THE DISEASE AND ITS EPIDEMIOLOGY
Hepatitis C June 2010 1) THE DISEASE AND ITS EPIDEMIOLOGY A. Etiologic Agent Hepatitis C (HCV) is caused by an RNA virus in the Flaviviridae family. Multiple HCV genotypes exist, with type 1 being most
More informationCommunity Health Administration
Community Health Administration 300 North San Antonio Road Santa Barbara, CA 93110-1332 805/681-5439 FAX 805/681-5200 Takashi M. Wada, MD, MPH Director/Health Officer Anne M. Fearon Deputy Director Suzanne
More informationLisa Y. Armitige, MD, PhD has the following disclosures to make:
Interferon Gamma Release Assays (IGRAs) Lisa Y. Armitige, MD, PhD May 13, 2015 TB for Pulmonologist Phoenix, AZ March 13, 2015 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following
More informationChanging Concept of FMD diagnostics: from Central to Local. Aniket Sanyal Project Directorate on FMD Mukteswar, India
Changing Concept of FMD diagnostics: from Central to Local Aniket Sanyal Project Directorate on FMD Mukteswar, India OBJECTIVES OF DIAGNOSIS IN THE FIELD/LOCAL 1. To arrive at quick diagnosis 2. To implement
More informationHepatitis B Virus (Pregnancy) Investigation Guideline
Hepatitis B Virus (Pregnancy) Investigation Guideline Contents CASE DEFINITION... 3 LABORATORY ANALYSIS... 3 BACKGROUND... 4 NOTIFICATION TO PUBLIC HEALTH... 5 INVESTIGATOR RESPONSIBILITIES... 6 STANDARD
More informationYes, I know I have genital herpes:
Counseling Messages for Herpes Simplex Type II (HSV-II) Genital herpes Always take the time to attend to the participant s feelings and emotional state; for some people, this is the most devastating news
More informationUse of Nucleic Acid Amplification Tests in TB patients in California 2010-2012
Use of Nucleic Acid Amplification Tests in TB patients in California 2010-2012 Lisa Pascopella, PhD, MPH Pennan Barry, MD, MPH Tuberculosis Control Branch, Division of Communicable Disease Control, Center
More informationHIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline
HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline Background... 2 Screening... 2 Recommendations... 2 Ordering and consent... 2 Indications for Periodic HIV Screening...
More informationParvovirus B19 Infection in Pregnancy
Parvovirus B19 Infection in Pregnancy Information Pack Parvovirus B19 Infection in Pregnancy Information Booklet CONTENTS: THE VIRUS page 3 CLINICAL MANIFESTATIONS page 6 DIAGNOSIS page 8 PATIENT MANAGEMENT
More informationLancet Device Incident Investigation Report - 2012
Lancet Device Incident Investigation Report - 2012 Summary On May 16, 2012 the Winnipeg Regional Health Authority (WRHA) received notification from the University of Manitoba (U of M) of an incident at
More informationUnderstanding the Western Blot
Understanding the Western Blot By Carl Brenner Revised: September, 1996 Inquiries about various issues relating to Western blot (WB) testing are frequently posted to the Lyme disease discussion groups
More informationRapid HIV Testing of Clients of a Mobile STD/HIV Clinic ABSTRACT
AIDS PATIENT CARE and STDs Volume 19, Number 4, 2005 Mary Ann Liebert, Inc. Rapid HIV Testing of Clients of a Mobile STD/HIV Clinic THOMAS S. LIANG, M.P.H., 1 EMILY ERBELDING, M.D., M.P.H., 3 CLAUDE A.
More informationViral Hepatitis Case Report
Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date
More informationInfectious Disease Markers (IDMs) Data
Instructions for Infectious Disease Markers Form (Form 2004 Revision 4) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Infectious Disease Markers Form.
More informationLYME DISEASE. 2.5M specimen tests per year. 97% accuracy with Rockland tools
LYME DISEASE The current situation & our solutions Lateral Flow Data Proof of Concept Studies Core Technology Sequence Analysis & Protein Expression The most common vector-borne illness in the United States
More informationAbout Our Products. Blood Products. Purified Infectious/Inactivated Agents. Native & Recombinant Viral Proteins. DNA Controls and Primers for PCR
About Our Products Purified Infectious/Inactivated Agents ABI produces a variety of specialized reagents, allowing researchers to choose the best preparations for their studies. Available reagents include
More informationUse of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors
This document is scheduled to be published in the Federal Register on 01/08/2016 and available online at http://federalregister.gov/a/2016-00149, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationPerformance Evaluation and Clinical Application of MTB NAAT in Orange County, CA. Minoo Ghajar Orange County Public Health Laboratory
Performance Evaluation and Clinical Application of MTB NAAT in Orange County, CA Minoo Ghajar Orange County Public Health Laboratory TB Case Count and Rate: Orange County, CA and the United States, 2012
More informationChapter 1 Overview of Tuberculosis Epidemiology in the United States
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States.... 3 TB Disease Trends in the United
More informationDirect Testing Systems and Serology
Direct Testing Systems and Serology Rapid Manual Tests 6-2 Serology Diagnostics 6-6 BD Diagnostics Diagnostic Systems Catalog 2005/2006 6-1 Rapid Manual Tests Meningitis Test Systems 252360 Directigen
More informationHepatitis C Virus Infection: Prevalence Report, 2003 Data Source: Minnesota Department of Health HCV Surveillance System
Hepatitis C Virus Infection: Prevalence Report, 2003 Data Source: Minnesota Department of Health HCV Surveillance System P.O. Box 9441 Minneapolis, MN 55440-9441 612-676-5414, 1-877-676-5414 www.health.state.mn.us/immunize
More informationTesting for Tick Borne Diseases: How and When?
Testing for Tick Borne Diseases: How and When? Rick Alleman, DVM, PhD University of Florida C. Guillermo Couto, DVM The Ohio State University Tick borne diseases (TBDs) used to be quite common in Greyhounds,
More informationHow can herpes simplex spread to an infant?
CHAPTER 3 HERPES AND PREGNANCY As an expectant parent eagerly awaiting the birth of your new baby, you are probably taking a number of steps to ensure your baby s health. One step many experts recommend
More informationViral load testing. medical monitoring: viral load testing: 1
medical monitoring: viral load testing: 1 medical monitoring: viral load testing Viral load testing medical monitoring: viral load testing: 2 Slide 1 Viral load The viral load test measures HIV in the
More informationPediatric HIV - The World At It's Best
VIH/SIDA en Pediatría: Epidemiología Mundial, Transmisión Perinatal, Manejo Integral. Juan Carlos Salazar, M.D. Universidad de Connecticut, EE.UU. End-1998 global estimates Children (
More informationHIV/AIDS: General Information & Testing in the Emergency Department
What Is HIV? HIV/AIDS: General Information & Testing in the Emergency Department HIV is the common name for the Human Immunodeficiency Virus. HIV is a retrovirus. This means it can enter the body s own
More informationVARICELLA ZOSTER (VZ) VIRUS, CHICKENPOX & SHINGLES GUIDANCE
VARICELLA ZOSTER (VZ) VIRUS, CHICKENPOX & SHINGLES GUIDANCE Summary This guidance provides background information on varicella zoster (VZ), chickenpox and shingles and sets out the infection control measures
More informationAnimal Health Diagnostic Center. Lyme Disease Multiplex Testing for Dogs. Background on Lyme disease and Lyme diagnostics in dogs
Animal Health Diagnostic Center Lyme Disease Multiplex Testing for Dogs Background on Lyme disease and Lyme diagnostics in dogs Lyme disease is induced by the spirochete B. burgdorferi. Spirochetes are
More informationViral Safety of Plasma-Derived Products
Viral Safety of Plasma-Derived Products SLIDE 1 This presentation will cover viral validation studies for plasma-derived products. FDA requires that the manufacturing process for biopharmaceutical products
More informationSolid Organ Transplantation
Solid Organ Transplantation Infection Prevention And Control Transplant Atlantic 2011 October 13/2011 Kathy Hart Introduction In the past several years, the drugs that we use, the surgeries themselves,
More informationBiopharmaceutical Process Evaluated for Viral Clearance
Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate
More information